CONCLUSIONS: Our observed PCa associations with BRCA2 and ATM are consistent with previous reports in high-risk men. BRCA2 may contribute to younger age of onset in high-risk cases, whereas ATM is associated with earlier onset in low-risk cases. These preliminary results from our large, ongoing collaborative study provide additional evidence supporting the contribution of germline PVs in DNA repair genes to PCa development.
INTRODUCTION AND OBJECTIVES:
Across all cancer sites and stages, prostate cancer has one of the greatest median 5-year survival rates. With this comes a focus on survivorship issues following diagnosis and treatment. In the current study we sought to evaluate the prevalence and predictors of depressive symptoms in a large, contemporary, prospectively collected sample of newly diagnosed men with prostate cancer.
METHODS: Data from the current study were drawn from the RADICAL PC study, a parent prospective cohort study conducted across 13 sites in Canada. Men with a diagnosis of prostate cancer within 12 months were recruited (2017-ongoing). Depressive symptoms were evaluated using the 9 item version of the Patient Health Questionnaire (PHQ-9). A score of 8 or higher on this scale represents clinically relevant depressive symptoms. To evaluate predictors of depressive symptoms, a logistic regression model was constructed including biological, psychological, and social predictor variables. RESULTS: Data from 1440 patients were available at the time of this analysis. Of these, 108 (7.5%) endorsed clinically significant burden of depressive symptoms. Having a pre-existing diagnosis of depression or anxiety disorder increased risk of depressive symptoms at the time of evaluation (OR[4.12, p<0.001 [2010] [2011] [2012] [2013] [2014] [2015] METHODS: We queried the National Cancer Database and included men of two non-overlapping cohorts: (1) men with a life expectancy <10 years harbouring prostate cancer of any risk group and (2) men with life expectancy !10 years with low-risk prostate cancer. Multivariable mixed models with patient characteristics as fixed and hospital-level intercept as random effect were used to assess the hospital-level risk-adjusted probability of definitive treatment (radical prostatectomy or radiation therapy within 180 days from diagnosis) in both groups. Pearson's correlation coefficient was calculated to investigate the correlation between the hospitals probabilities of treating patients of both cohorts RESULTS: We found 58,903 men with a life expectancy <10 years and 122,514 men with a life expectancy !10 years and low-risk prostate cancer. In the latter, the probability of treatment ranged from 29.0% in the bottom to 90.0% in the top decile and from 38.6% to 88.7% for men with a life expectancy <10 years. Age, black race and not having insurance were independent predictors of low-value treatment in both cohorts. The correlation between hospitals treating men of both cohorts was strong (Pearson's r[0.64, p<0.001).
CONCLUSIONS: There is wide hospital-level variability in lowvalue treatment of men with limited life expectancies and low-risk prostate cancer. Hospitals more likely to treat men with limited life expectancies were more likely to treat men with low-risk prostate cancer and vice versa. Identifying drivers and modifying practice at these hospitals may represent an effective tool for reducing overtreatment.
